1. Introduction {#sec1-antibiotics-09-00423}
===============

The indiscriminate use of antibiotics accelerates the process of selection and dissemination of bacterial resistance, estimated by the Spanish Society of Infectious Diseases and Clinical Microbiology to lead to 26,000 deaths every year in Spain \[[@B1-antibiotics-09-00423]\] and to cost €1500 million per year in the European Union \[[@B2-antibiotics-09-00423]\]. The implementation of regulations to control and monitor the prescription of these drugs is essential in the current context of raising awareness on the use of antibiotics. Changes to pharmaceutical copayment, adjustment of antibiotics packaging (fixing the appropriate number of pills for the most common type of infection), and approval of a National Program Against Bacterial Resistance (PRAN) are three policies recently applied in Spain.

To improve the public health deficit, worsened by the economic crisis of 2008, Royal Decree-Law (RDL) no. 16/2012 was introduced in Spain, containing urgent measures to guarantee the sustainability of the National Health System and the quality and safety of its services \[[@B3-antibiotics-09-00423]\]. Pharmaceutical copayments became income-based: Pensioner copayment was raised from zero to 10% (with monthly limits of €8.26 and €18.59 for annual incomes below €18,000 and €100,000, respectively), and the working population copayment rose from 40% to 50% on annual income greater than €18,000 and to 60% on annual income over €100,000. Some Autonomous Communities tried to avoid implementing these new pharmaceutical copayments in the belief that the universality of the public health system was not guaranteed. As established by Law 14/1986, in Spain, each Autonomous Community administers a Regional Health Service in order to bring the management of health care closer to the citizen and thus provide guarantees in terms of equity, quality, and participation \[[@B4-antibiotics-09-00423]\]. The Autonomous Community of the Basque Country managed to delay the application of RDL until July 2013 through Decree no. 114/2012 \[[@B5-antibiotics-09-00423]\], when the Constitutional Court annulled it in December 2012 \[[@B6-antibiotics-09-00423]\]. This Autonomous Community of northern Spain has a population of more than two million \[[@B7-antibiotics-09-00423]\]. Its public health service has a per capita budget of €1731 (year 2019), exceeding the national average by 30.3% and giving the region top position among the Autonomous Communities \[[@B8-antibiotics-09-00423]\]. Its financing system is different from the other regions since it has its own tax system, so it was possible to delay the entry into force of the RDL until the Supreme Court obliged to implemented in July 2013. There was already a national analysis that estimated that a copayment policy reduced the consumption of medicinal products by 12% (both number of prescriptions and costs) \[[@B9-antibiotics-09-00423]\], but it is interesting to see if these results are maintained in the Basque Health Service.

The RDL not only made pharmaceutical copayment income-based, but it also introduced regulations to adjust drug packaging to fit the actual duration of the treatment. During the process to approve new medicines, AEMPS, a state agency working as part of the Spanish Ministry of Health since 1999, also evaluates the format in which it is administered. For previously introduced drugs, adjustments were made to the number of units per package \[[@B10-antibiotics-09-00423]\]. With this objective, in 2012, a legislative measure was approved, the fourth additional provision \[[@B11-antibiotics-09-00423]\] of RDL no. 16/2012, which changed the format of certain drugs. The aim of this was to ensure that packaging is suitable for the treatment and to reduce economic impact. Drug marketing companies had a period of six months (until January 2013) from the RDL coming into force (July 2012) to withdraw old formats and distribute new ones. However, due to pressure from pharmaceutical companies, this period was extended until May 2013, and even then, drugs could be kept in their old formats until June 2013. This meant that the old formats could no longer be sold from July 2013 \[[@B12-antibiotics-09-00423]\]. Drugs belonging to therapeutic group J01 (Antibacterials for systemic use) were the first drugs to undergo the review and improvement of their administration formats, based on the recommendations of the health authorities to alter clinical practices to prevent the generation of bacterial resistance.

To reduce the risk of selection and spread of antibiotic resistance, in June 2014, the Inter-territorial Council of the National Health System approved PRAN \[[@B13-antibiotics-09-00423]\]. This program included six strategic lines in human health, and its objectives focused on monitoring the consumption of antibiotics and raising public awareness. PRAN set a four-year deadline, after which time the effects on consumption should be visible. The effects of this type of program have not been studied in-depth, and few comparisons can be found in literature. Studies monitoring the consumption of antibiotics predominate in different contexts, such as hospitals \[[@B14-antibiotics-09-00423],[@B15-antibiotics-09-00423]\] and primary care \[[@B16-antibiotics-09-00423],[@B17-antibiotics-09-00423],[@B18-antibiotics-09-00423],[@B19-antibiotics-09-00423]\]. All of them conclude with the recommendation not only to introduce health policies to reduce the consumption of these drugs but also to quantify the results. Currently, it is known that introducing these policies significantly reduces the consumption of antibiotics within one year, in both hospital settings \[[@B20-antibiotics-09-00423],[@B21-antibiotics-09-00423]\] and primary care \[[@B22-antibiotics-09-00423]\].

In July 2013, an economic policy, based on changes in copayment rates, and a health policy, based on the adjustment of drug packaging, were applied in the Basque Country. A year later, an additional national program to monitor the consumption of antibiotics was also approved. This study focuses on the Regional Health Service of the Basque Country, following the recommendation by AEMPS to ensure the exploitation and analysis of data on antibiotics consumption at regional level \[[@B23-antibiotics-09-00423]\]. The objective of this study is to analyze the effect of the change to the copayment rate, the adjustment of drug packaging, and the approval of the PRAN on the consumption of antibiotics, depending on the type of active ingredient prescribed, in the Basque Country.

2. Materials and Methods {#sec2-antibiotics-09-00423}
========================

The database containing all monthly antibiotic prescriptions (therapeutic group J01) in Primary Care from January 2009 to December 2018 in the Basque Country was available. The Basque Government Pharmacy Department provided the data, disaggregated by date of prescription (month and year), active ingredient administered (dose, number of packages, number of prescriptions, and retail price), and patient data (sex, age, and rate of copayment, which is income-based). The doses were given in defined daily doses (DDD). As indicated in the World Health Organization (WHO) methodology, this unit of measurement is subject to continuous variations in order to ensure its representativeness, as it seeks to indicate the maintenance dose in the main indication for a route of administration \[[@B24-antibiotics-09-00423]\]. DDDs are usually determined for consumption in adults, unless specifically calculated for consumption in children, as is the case for the database used in this study. In order to compare these results with other studies, DDDs were transformed into defined daily doses per thousand people per day (DID), by multiplying by one thousand and dividing then by 365 days times the number of inhabitants. For the population values, data was taken from the Spanish National Institute of Statistics (Spanish acronym: INE) as at July 1 of the corresponding year.

It is important \[[@B25-antibiotics-09-00423]\] to perform these analyses disaggregating by active ingredient, since differences may depend on the bacterial group. The average cost per prescription in the Basque Country \[[@B26-antibiotics-09-00423]\] is €12.71: two active ingredients with a high cost per prescription, cefditoren (€43/prescription) and moxifloxacin (€24/prescription), and two active ingredients with a low cost per prescription, doxycycline (€5/prescription) and cloxacillin (€4/prescription), were selected. The most prescribed active ingredient, amoxicillin (representing 23% of all prescribed antibiotics), amoxicillin and beta-lactamase inhibitors (21%), azithromycin (12%), and levofloxacin (5%) were also selected. Except for cefditoren and moxifloxacin, all the drugs were included in the regulations on adjustment to drug packaging. The 2019 AWaRe classification (Access, Watch, and Reserve) issued by the WHO classifies J01 active ingredients in three groups, depending on their probability of generating antibiotic resistance, as follows: 'access group antibiotics' for first-line treatment, 'watch group antibiotics' for those with a relatively high risk of selection of bacterial resistance, and 'reserve group antibiotics' for suspected infections due to multi-drug-resistant organisms only \[[@B27-antibiotics-09-00423]\]. This classification is used to compare results by groups, with the active ingredients doxycycline, cloxacillin, and amoxicillin belonging to the 'access' group, and cefditoren, moxifloxacin, azithromycin, and levofloxacin belonging to the 'watch' group.

As time series were available, analysis was performed according to the Box-Jenkins methodology, frequently \[[@B28-antibiotics-09-00423],[@B29-antibiotics-09-00423]\] applied for monthly databases of antibiotic consumption. To estimate the impact of RDL no. 16/2012, counterfactual analysis was performed with the first 53 observations (from January 2009 to May 2013), which allowed for predictions and confidence intervals (80%, commonly applied because it establishes an adequate relationship between precision and width of the interval \[[@B30-antibiotics-09-00423]\]). If the real value was in the confidence interval of the forecast for the same period, it could be concluded that the policy no longer had a significant effect. Furthermore, the difference between the real value and the predicted value represented the potential savings of the policy under analysis. To understand the impact of the PRAN under approval, intervention analysis was performed that included a dummy variable (V), created to capture the effects of the introduction of RDL no. 16/2012. This variable was at value 1 in June 2013, the month prior to the implementation of copayment, to quantify the stockpiling effect, and the value −1 from July 2013 to the month when the reduction in consumption was no longer significant, according to the results of the previous counterfactual analysis. From January 2009 to June 2015 (one year after approval), 66 observations were made for the intervention analysis.

Box-Jenkins analysis was performed using different packages of R, a software environment for statistical computing and graphics, in order to: represent and break down the variables according to season; obtain the autocorrelation function (ACF) and partial autocorrelation function (PACF), select the best ARIMA model (Autoregressive integrated moving average) according to the Akaike information criterion (AIC), chosen for this study out of the others available (BIC or AICc); and make forecasts for various periods with a confidence level and verify with the Ljung-Box test whether the model adequately captured the information of the observed values and to check that there was no information in the residuals that could be used to make the predictions.

3. Results {#sec3-antibiotics-09-00423}
==========

3.1. Copayment and Adjustment of Packaging {#sec3dot1-antibiotics-09-00423}
------------------------------------------

To understand the impact of RDL no. 16/2012, counterfactual analysis was performed, which examined the first 53 observations, from January 2009 to May 2013 ([Table 1](#antibiotics-09-00423-t001){ref-type="table"}). The predictions obtained for June 2013, the month prior to implementation of the RDL, showed an increase in the administration of antibiotics in the series of costs, number of packages and DID, of 8.31%, 7.21%, and 7.44%, respectively. For the packaging series, all predictions for one year after the policy was applied were significant, resulting in savings of 12.19%. For the costs and DID series, all the observed values fell within the confidence intervals of the predictions, except in July 2013, meaning the policy led to a significant reduction in terms of spending and DID, of 2.20% and 2.07%, respectively (see [Appendix A](#app1-antibiotics-09-00423){ref-type="app"}, [Table A1](#antibiotics-09-00423-t0A1){ref-type="table"}, for calculations of savings).

The analysis by active substance showed that, for 'watch' group drugs, whether they were included in the regulations (azithromycin and levofloxacin) or not (cefditoren and moxifloxacin), there was no significant decrease in the number of packages prescribed. With regard to the active substance of the 'access' group, on the other hand, the regulation had a significant effect in reducing the number of packages prescribed (see [Table A2](#antibiotics-09-00423-t0A2){ref-type="table"} for analysis and [Table A3](#antibiotics-09-00423-t0A3){ref-type="table"} for savings).

3.2. PRAN Approval {#sec3dot2-antibiotics-09-00423}
------------------

To estimate the impact of the approval of the PRAN on the consumption of antibiotics, intervention analysis was performed ([Table 2](#antibiotics-09-00423-t002){ref-type="table"}) that took into account the first 66 observations, from January 2009 to June 2015 (one year after approval). V1 was used for the cost and DID models, and V2 for the packaging model, taking into account the results of the previous section on the introduction of RDL no. 16/2012. The coefficients of V1 (−0.019 in the cost series and −0.015 in the DID series) and V2 (−0.093 in the packaging series) show that the RDL significantly reduced consumption, corroborating the results obtained in the previous section (see [Table A4](#antibiotics-09-00423-t0A4){ref-type="table"} for calculations of savings).

The consumption of antibiotics during the year after approval of the PRAN showed a decrease in expenditure by 7.96%, prescribed packages by 8.87%, and the DID by 0.779, mainly with reference to doses of amoxicillin (−0.277 DID), amoxicillin and inhibitors (−0.193 DID) and azithromycin (−0.174 DID), with the latter belonging to the 'surveillance antibiotics' group (see [Table A5](#antibiotics-09-00423-t0A5){ref-type="table"} for analysis and [Table A6](#antibiotics-09-00423-t0A6){ref-type="table"} for calculations).

[Figure A1](#antibiotics-09-00423-f0A1){ref-type="fig"} shows the graph of the antibiotic time series expressed in €, packages, and DID. It marks the entry into force of the change in copayment rates, adjustment of packages, and approval of the PRAN. The black line represents monthly prescription values, and the dashed line shows forecasts (80% confidence interval) obtained in counterfactual analysis.

4. Discussion {#sec4-antibiotics-09-00423}
=============

As in other studies \[[@B9-antibiotics-09-00423],[@B31-antibiotics-09-00423]\] that found a stockpiling effect prior to implementation of the copayment policy, this analysis also detected an 8% increase in the consumption of antibiotics in June 2013. The Basque Government Health Department issued a statement \[[@B26-antibiotics-09-00423]\] two months after the copayment implementation, confirming that there had been a stockpiling effect in June 2013, whereby patients purchased 5.03% more drugs compared to June the previous year. As a consequence of applying the RDL, a reduction was only found in the number of packages prescribed, which did not affect DID nor the cost of antibiotics (series that only presented statistically significant reductions in July 2013). According to the Basque Health Department \[[@B26-antibiotics-09-00423]\], 'historically, the summer months record lower consumption data than the rest of the year', but for 2013 these data were significantly higher. Therefore, these results can be attributed to the introduction of the policy to adjust packaging units to fit the treatment, which, despite being an additional provision of the copayment RDL, was only implemented simultaneously with the changes to copayment in the Basque Country. In a study carried out in 20 European countries, copayment schemes were determinant in antibiotic consumption. The purchasing of antibiotics under copayment schemes was 10% lower than in a scheme with full reimbursement system \[[@B32-antibiotics-09-00423]\]. In addition, in another country-based study, the implementation of a copayment policy had a negative effect of 4% on the consumption of antibiotics for every €1 increase in copayment \[[@B33-antibiotics-09-00423]\].

Studies on antibiotic dose adjustment are usually placed in a hospital setting. A recent study established that the personalized dosage of antibiotics in hospitalized patients reduces the inappropriate use of these drugs \[[@B34-antibiotics-09-00423]\]. In this study, the adjustment of packaging was studied in a Primary Care setting. This policy affected 'access group antibiotics', those that are used as first-line treatment and, therefore, are more frequently prescribed. As indicated before, this decrease in the number of packages prescribed did not translate into a reduction for the other series analyzed; it can therefore be deduced that fewer packages were prescribed, but with a higher drug load and price. This was the only measure that could reduce self-consumption, by preventing the prescribed dose from exceeding the treatment indicated by the healthcare professional, since patients would have a smaller surplus. However, there are no records to quantify the self-consumption of antibiotics.

In a study undertaken in Belgium, it was found that consumption of antibiotics was reduced by 12.8% DID after an antibiotic awareness campaign was implemented \[[@B35-antibiotics-09-00423]\]. In other Spanish Regional Services, the consumption of antibiotics was reduced by 5% (both packages and expenditure) after an awareness and rational use campaign was introduced \[[@B36-antibiotics-09-00423]\]. The first available data on the consumption of antibiotics in Spain coincide with the approval of the PRAN in 2014. According to the PRAN database \[[@B37-antibiotics-09-00423]\], the consumption of antibiotics in the Basque Country decreased by 0.610 DID, 3.64% from 2015 (16.740 DID) to 2016 (16.130 DID). Our analysis estimated that approval of the PRAN would lead to a reduction of 0.779 DID prescribed, equivalent to a decrease of 4.51% from July 2015 to June 2016. However, this decrease is lower than that estimated for spending and the prescribed quantity expressed in packages (7.96% and 8.87%, respectively). This analysis recorded the greatest reductions in the most frequently prescribed active substances, amoxicillin and azithromycin, classified as 'watch group antibiotics'. It should be noted that DIDs are reviewed annually by the WHO in order to assess their representativeness and that their main objective is to serve as a tool for monitoring drug consumption. When a modification is introduced, the entire time series is corrected so that the values are comparable (in the style of a deflator). In contrast, variations in prices (e.g., generic approval) and packaging (e.g., single-dose packaging) do not make this correction throughout the time series.

One of the strengths of this study is that it performs analysis at the decision-making level. In addition, it uses the Regional Health Authority database of all prescriptions of antibiotics in primary care, which avoids sample-based analysis. One limitation of this study is that the prescription of antibiotics does not correspond to actual consumption (some packages may not be consumed or patient may take leftover drugs). Despite this, antibiotic prescriptions are the closest proxy variable to actual consumption. Another limitation is the use of DDD, which is recommended to monitor consumption in adults, but it has also been applied to pediatric prescriptions as there are no exact values for this group. However, this study included pediatric use as the Basque Health Authority already had internal estimations and provided us with this information.

As a conclusion of this study, it may be pointed out that, despite the delay in applying the copayment, the characteristic stockpiling effect of this type of policy follows the same trend as for the rest of the country. In addition, the adjustment of prescription formats reduced the number of packages, by 12.19%, but did not reduce the trend in either the dose or the expenditure. Finally, the approval of the PRAN effectively reduced the consumption of antibiotics, by 4.51%, not only for those indicated as first-line treatment but also for 'watch group antibiotics'.
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antibiotics-09-00423-t0A1_Table A1

###### 

Savings from the introduction of RDL no. 16/2012 (predictions with the ARIMA models in [Table 1](#antibiotics-09-00423-t001){ref-type="table"}).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Series                Costs (euros)   Packages     DID                                                                                       
  --------------------- --------------- ------------ ---------------------- ------------ ------------ ------------------ ---------- ---------- --------------
  **Jun. 2013**         994,437 \*      918,145 \*   843,114--993,176       125,760 \*   117,301 \*   109,310--125,474   1.286 \*   1.197 \*   1.111--1.283

  **Jul. 2013**         778,627 \*      894,975 \*   790,709--999,241       95,966 \*    106,961 \*   98,926--114,997    0.975 \*   1.112 \*   1.025--1.197

  **Aug. 2013**         677,717         716,160      598,665--833,655       84,092 \*    92,684 \*    84,118--101,350    0.882      0.940      0.849--1.030

  **Sep. 2013**         890,812         818,366      700,871--935,862       100,232 \*   106,253 \*   100,587--114,920   1.131      1.088      0.996--1.179

  **Oct. 2013**         1,022,801       1,039,945    922,450--1,157,440     115,925 \*   126,973 \*   118,307--135,640   1.269      1.295      1.204--1.387

  **Nov. 2013**         992,537         1,064,936    947,441--1,182,431     117,578 \*   131,980 \*   123,313--140,646   1.329      1.337      1.246--1.429

  **Dec. 2013**         1,185,331       1,080,010    962,515--1,197,506     129,174 \*   139,341 \*   130,675--148,007   1.500      1.412      1.320--1.503

  **Jan. 2014**         1,320,501       1,231,031    1,113,536--1,348,526   131,722 \*   149,125 \*   140,461--157,789   1.652      1.562      1.471--1.653

  **Feb. 2014**         1,051,123       1,112,522    995,027--1,230,018     106,900 \*   140,592 \*   131,928--149,255   1.366      1.456      1.365--1.548

  **Mar. 2014**         1,047,866       1,126,069    1,008,573--1,243,564   110,981 \*   143,465 \*   134,802--152,129   1.399      1.484      1.392--1.575

  **Apr. 2014**         956,060         1,047,480    929,984--1,164,975     105,361 \*   123,841 \*   115,177--132,505   1.246      1.283      1.192--1.374

  **May 2014**          954,021         1,033,550    916,055--1,151,046     108,572 \*   129,514 \*   120,851--138,178   1.233      1.318      1.227--1.410

  **Jun. 2014**         884,376         1,000,323    882,827--1,117,818     99,485 \*    122,447 \*   113,783--131,110   1.152      1.240      1.148--1.331

  Total (\*)            1,773,064       1,813,120                           1,431,748    1,630,477                       2.261      2.309      

  Difference (\*)       −40,056         −198,729     −0.048                                                                                    

  Variation (\*)        −2.20%          −12.19%      −2.07%                                                                                    

  Stockpiling effect\   8.31%                        7.21%                               7.44%                                                 
  (var. Jun. 2013)                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

(\*) Only statistically significant predictions are included in the calculation; RDL (Royal Decree-Law); DID (daily defined doses per thousand people). Source: Own elaboration based on data provided by the Basque Government Pharmacy Department.

antibiotics-09-00423-t0A2_Table A2

###### 

Counterfactual analysis of the series of costs and packages by active substance. Real values from January 2009 to May 2013 and predictions from June 2013 to June 2014.

  --------------------------------------------------------------------------------------- ------------------------------------ ----------------------------------------------------------------------- ------------------------------------ ----------------------------------------------------------------------- ----------------- ----------------------------------------------------------------------- ----------------- -----------------
  **Active Substance**                                                                    **Cefditoren**                       **Moxifloxacin**                                                        **Doxycycline**                      **Cloxacillin**                                                                                                                                                                     

  Group                                                                                   "watch"                              "watch"                                                                 "access"                             "access"                                                                                                                                                                            

  Chosen by                                                                               High cost (€43/recipe)               High cost (€24/recipe)                                                  Low cost (€5/recipe)                 Low cost (€4/recipe)                                                                                                                                                                

  Included in RDL                                                                         No                                   No                                                                      Yes                                  Yes                                                                                                                                                                                 

  Serie                                                                                   Costs (euros)                        Packages                                                                Costs (euros)                        Packages                                                                Costs (euros)     Packages                                                                Costs (euros)     Packages

  ARIMA model                                                                             (0,0,1) (1,1,0)                      (0,0,1) (1,1,0)                                                         (0,0,1) (1,1,0)                      (1,0,2) (1,1,0)                                                         (2,0,0) (0,1,1)   (0,1,1) (0,1,1)                                                         (2,0,0) (1,1,0)   (1,0,2) (1,1,0)

  AR1                                                                                     \-                                   \-                                                                      \-                                   0.48345 \*                                                              0.29353 \*        \-                                                                      0.29846 \*        0.773629 \*\*\*

  AR2                                                                                     \-                                   \-                                                                      \-                                   \-                                                                      0.37230 \*        \-                                                                      −0.34330 \*\*     \-

  MA1                                                                                     0.41060 \*\*                         0.42849 \*\*                                                            0.83520 \*\*\*                       0.31378 \*                                                              \-                −0.632895 \*\*\*                                                        \-                0.369473\*

  MA2                                                                                     \-                                   \-                                                                      \-                                   −0.40898 \*                                                             \-                \-                                                                      \-                0.150730 \*

  SAR1                                                                                    −0.53195 \*\*\*                      −0.55235 \*\*\*                                                         −0.65118 \*\*\*                      −0.49804 \*\*                                                           \-                \-                                                                      −0.54423 \*\*     −0.503722 \*

  SMA1                                                                                    \-                                   \-                                                                      \-                                   \-                                                                      −0.56709 \*       −0.400906 \*                                                            \-                \-

  Q test (*p*-value, delay 18)                                                            7.4520 (0.5962)                      7.7591\                                                                 7.3600 (0.5997)                      7.4616\                                                                 10.337\           7.8494\                                                                 10.721\           8.6277\
                                                                                                                               (0.5586)                                                                                                     (0.3824)                                                                (0.2422)          (0.5494)                                                                (0.218)           (0.2805)

  AIC                                                                                     −10.764                              −10.130                                                                 −11.577                              −10.929                                                                 −9.03q            −10.878                                                                 −8.825            −9.405

  Residual sum of squares                                                                 0.0604                               0.0595                                                                  0.0624                               0.0605                                                                  0.0824            0.0557                                                                  0.0793            0.0655

  Standard error of the regression                                                        0.0472                               0.0443                                                                  0.0511                               0.0502                                                                  0.0712            0.0466                                                                  0.069             0.0583

  Effect on the series\                                                                   not significant                      not significant                                                         not significant                      Stockpiling effect of 7.63%\                                            not significant   Stockpiling effect of 7.23%\                                                              
  (calculations of savings in [Table A3](#antibiotics-09-00423-t0A3){ref-type="table"})                                                                                                                                                     Packaging reduction of 19.68%\                                                            Packaging reduction of 23.62%\                                                            
                                                                                                                                                                                                                                            including Jun. 2013 to Jun. 2014 (last month with significant effect)                     including Jun. 2013 to Jun. 2014 (last month with significant effect)                     

  **Active Substance**                                                                    **Amoxicillin**                      **Amoxicillin and Inhibitors**                                          **Azithromycin**                     **Levofloxacin**                                                                                                                                                                    

  Group                                                                                   "access"                             "access"                                                                "watch"                              "watch"                                                                                                                                                                             

  Chosen by                                                                               High prescription (23% of recipes)   High prescription (21% of recipes)                                      High prescription (12% of recipes)   High prescription (5% of recipes)                                                                                                                                                   

  Included in RDL                                                                         Yes                                  Yes                                                                     Yes                                  Yes                                                                                                                                                                                 

  Serie                                                                                   Costs (euros)                        Packages                                                                Costs (euros)                        Packages                                                                Costs (euros)     Packages                                                                Costs (euros)     Packages

  ARIMA model                                                                             (1,1,0) (1,1,0)                      (1,0,0) (1,1,0)                                                         (1,0,0) (1,1,0)                      (0,0,1) (1,1,0)                                                         (0,1,2) (0,1,1)   (0,1,2) (1,1,0)                                                         (0,1,2) (1,1,0)   (0,0,1) (0,1,1)

  AR1                                                                                     0.75416 \*\*                         0.807218 \*\*\*                                                         0.822603 \*\*\*                      \-                                                                      \-                \-                                                                      \-                \-

  AR2                                                                                     \-                                   \-                                                                      \-                                   \-                                                                      \-                \-                                                                      \-                \-

  MA1                                                                                     \-                                   \-                                                                      \-                                   0.524390 \*\*\*                                                         −0.12776 \*       −0.11887 \*                                                             0.44500 \*\*\*    0.61486 \*\*\*

  MA2                                                                                     \-                                   \-                                                                      \-                                   \-                                                                      −0.48812 \*\*     −0.50298 \*                                                             0.04571 \*\*\*    \-

  SAR1                                                                                    −0.57297 \*\*                        −0.365231 \*\*                                                          −0.358346 \*\*                       −0.55124 \*\*                                                           \-                −0.55869 \*\*\*                                                         −0.31785 \*\*\*   \-

  SMA1                                                                                    \-                                   \-                                                                      \-                                   \-                                                                      −0.33576 \*       \-                                                                      \-                −0.42197 \*\*

  Q test (*p*-value, delay 18)                                                            7.6307 (0.5997)                      13.476\                                                                 12.467\                              12.416\                                                                 13.514\           14.477\                                                                 9.2410 (0.1845)   2.0625 (0.9904)
                                                                                                                               (0.1422)                                                                (0.1882)                             (0.1909)                                                                (0.0953)          (0.0942)                                                                                  

  AIC                                                                                     −10.895                              −11.526                                                                 −11.094                              −11.118                                                                 −9.646            −9.054                                                                  −8.016            −17.643

  Residual sum of squares                                                                 0.0613                               0.0650                                                                  0.0649                               0.0646                                                                  0.0708            0.0696                                                                  0.0856            0.0545

  Standard error of the regression                                                        0.0495                               0.0866                                                                  0.0848                               0.0855                                                                  0.0917            0.0864                                                                  0.072             0.0387

  Effect on the series\                                                                   not significant                      Stockpiling effect of 9.16%\                                            not significant                      Stockpiling effect of 8.40%\                                            not significant   not significant                                                                           
  (calculations in [Table A2](#antibiotics-09-00423-t0A2){ref-type="table"})                                                   Packaging reduction of 26.79%\                                                                               Packaging reduction of 26.05%\                                                                                                                                                      
                                                                                                                               including Jun. 2013 to Jun. 2014 (last month with significant effect)                                        including Jun. 2013 to Jun. 2014 (last month with significant effect)                                                                                                               
  --------------------------------------------------------------------------------------- ------------------------------------ ----------------------------------------------------------------------- ------------------------------------ ----------------------------------------------------------------------- ----------------- ----------------------------------------------------------------------- ----------------- -----------------

Legend: (\*) significant level equal to or less than 0.05; (\*\*) significance level equal to or less than 0.01; (\*\*\*) level of significance equal to or less than 0.001; RDL (Royal Decree-Law); ARIMA (integrated autoregressive moving average model); AR1 (first autoregressive term); AR2 (second autoregressive term; MA1 (first moving average term), MA2 (second moving average term); SAR1 (first seasonal autoregressive term); SMA1 (first seasonal moving average term); AIC (Akaike reporting criterion). Source: Own elaboration from data provided by the Basque Government Pharmacy Department.

antibiotics-09-00423-t0A3_Table A3

###### 

Saving of the RDL no. 16/2012 introduction by active substance (predictions with the ARIMA models in [Table A2](#antibiotics-09-00423-t0A2){ref-type="table"}).

  ---------------------- ----------------- ----------------------------------------------- ------------------------------- ---------------- ---------------- -------------------------------
  **Series**\            **Packages**\     **Packages**\                                                                                                     
  **Active Substance**   **Doxycycline**   **Cloxacillin**                                                                                                   

  **Date**               **Real Value**    **Prediction**                                  **Confidence Interval (80%)**   **Real Value**   **Prediction**   **Confidence Interval (80%)**

  Jun. 2013              1410              1310                                            1217--1403                      2475             2308             2160--2456

  Jul. 2013              1009              1302                                            1210--1,395                     2371             2437             2398--2476

  Aug. 2013              802               1053                                            954--1151                       2168             2441             2376--2506

  Sep. 2013              1211              1319                                            1215--1423                      1985             2469             2383--2555

  Oct. 2013              1308              1628                                            1518--1737                      1790             2431             2329--2533

  Nov. 2013              1342              1659                                            1545--1774                      1641             2349             2233--2464

  Dec. 2013              1234              1543                                            1424--1662                      1536             2281             2154--2407

  Jan. 2014              1425              1745                                            1621--1869                      1544             2218             2081--2354

  Feb. 2014              1458              1794                                            1666--1923                      1567             2230             2085--2375

  Mar. 2014              1490              1902                                            1769--2035                      1565             2242             2089--2395

  Apr. 2014              1347              1792                                            1655--1930                      1557             2317             2157--2477

  May 2014               1271              1694                                            1553--1835                      1545             2356             2189--2522

  Jun. 2014              965               1517                                            1372--1662                      1521             2379             2207--2551

  Total                  16,272            20,258                                                                          23,265           30,458           

  Difference             −3986             −7193                                                                                                             

  Variation              −19.68%           −23.62%                                                                                                           

  Stockpiling effect\    7.63%                                                             7.23%                                                             
  (var. Jun. 2013)                                                                                                                                           

  **Series**\            **Packages**\     **Packages**\                                                                                                     
  **Active Substance**   **Amoxicillin**   **Amoxicillin and Beta-Lactamase Inhibitors**                                                                     

  **Date**               **Real Value**    **Prediction**                                  **Confidence Interval (80%)**   **Real Value**   **Prediction**   **Confidence Interval (80%)**

  Jun. 2013              34,671            31,763                                          28,860--34,662                  25,897           23,889           22,018--25,760

  Jul. 2013              22,177            25,553                                          22,672--28,433                  21,009           24,240           22,400--26,079

  Aug. 2013              17,158            21,420                                          17,719--25,122                  19,012           23,343           21,266--25,421

  Sep. 2013              24,811            30,277                                          26,127--34,427                  21,377           25,021           22,944--27,098

  Oct. 2013              31,244            35,922                                          31,504--40,340                  21,151           28,156           26,079--30,233

  Nov. 2013              36,462            41,326                                          36,742--45,910                  18,909           27,648           25,571--29,725

  Dec. 2013              31,615            43,703                                          39,014--48,393                  23,170           29,024           26,947--31,101

  Jan. 2014              29,702            42,492                                          37,735--47,248                  23,802           32,634           30,557--34,711

  Feb. 2014              24,601            43,483                                          38,684--48,283                  18,246           31,123           29,046--33,200

  Mar. 2014              25,047            43,360                                          38,532--48,188                  18,852           31,016           28,939--33,093

  Apr. 2014              21,518            33,168                                          28,322--38,014                  17,605           26,614           24,536--28,691

  May 2014               20,855            37,643                                          32,785--42,501                  17,288           27,619           25,541--29,696

  Jun. 2014              20,149            34,337                                          29,471--39,202                  16,864           25,570           23,493--27,647

  Total                  340,010           464,447                                                                         263,182          355,897          

  Difference             −124,437          −92,715                                                                                                           

  Variation              −26.79%           −26.05%                                                                                                           

  Stockpiling effect\    9.16%                                                             8.40%                                                             
  (var. Jun. 2013)                                                                                                                                           
  ---------------------- ----------------- ----------------------------------------------- ------------------------------- ---------------- ---------------- -------------------------------

Legend: RDL (Royal Decree-Law). Source: Own elaboration based on data provided by the Basque Government Pharmacy Department.

antibiotics-09-00423-t0A4_Table A4

###### 

Savings from PRAN approval (predictions with the ARIMA models in [Table 2](#antibiotics-09-00423-t002){ref-type="table"}).

  Series       Costs (euros)   Packages     DID                                                                                 
  ------------ --------------- ------------ ---------------------- ----------- ----------- ------------------ -------- -------- --------------
  Jul. 2015    821,322         866,160      828,657--903,663       92,620      96,947      92,666--101,228    1.137    1.185    1.160--1.211
  Aug. 2015    662,357         722,741      672,212--773,270       77,694      83,878      77,715--90,041     1.019    1.049    1.024--1.075
  Sep. 2015    864,798         926,602      874,631--978,573       98,640      105,538     98,962--112,115    1.227    1.262    1.237--1.288
  Oct. 2015    1,019,837       1,085,420    1,030,836--1,140,004   111,074     120,644     112,646--128,642   1.405    1.438    1.413--1.464
  Nov. 2015    972,651         1,042,835    984,719--1,098,951     107,508     117,163     108,265--126,061   1.405    1.458    1.433--1.484
  Dec. 2015    1,083,567       1,156,014    1,096,441--1,215,587   120,723     130,513     121,019--140,006   1.513    1.565    1.538--1.592
  Jan. 2016    1,060,474       1,234,741    1,172,778--1,296,704   120,736     133,723     123,332--144,115   1.736    1.824    1.797--1.851
  Feb. 2016    905,632         981,301      917,010--1,045,592     116,703     127,823     116,757--138,890   1.490    1.64     1.613--1.667
  Mar. 2016    1,044,753       1,123,100    1,056,539--1,189,661   117,945     130,498     118,828--142,169   1.540    1.618    1.591--1.645
  Apr. 2016    931,082         1,017,023    948,246--1,085,800     105,186     120,087     107,735--132,439   1.345    1.415    1.388--1.442
  May 2016     951,560         1,040,102    969,158--1,111,046     107,255     119,942     107,009--132,876   1.335    1.421    1.391--1.451
  Jun. 2016    864,528         954,471      881,408--1,027,534     97,951      111,215     97,719--124,711    1.292    1.345    1.315--1.375
  Total        11,182,561      12,149,510                          1.274.035   1.397.972                      16.441   17.220   
  Difference   −966,949        −123,937     −0.779                                                                              
  Variation    −7.96%          −8.87%       −4.51%                                                                              

Legend: DID (daily defined doses per thousand people). Source: Own elaboration based on data provided by the Basque Government Pharmacy Department.

antibiotics-09-00423-t0A5_Table A5

###### 

Intervention analysis of the costs and DID series by active principle. Real values from January 2009 to June 2015 and predictions from July 2015 to June 2016 with dummy variable V1.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Active Substance                                                                        Amoxicillin                          Amoxicillin and Inhibitors           Azithromycin                                                             
  --------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ --------------- ------------------- ------------------
  Group                                                                                   "access"                             "access"                             "watch"                                                                  

  Chosen by                                                                               High prescription (23% of recipes)   High prescription (21% of recipes)   High prescription (12% of recipes)                                       

  **Series**                                                                              **Costs (euros)**                    **DID**                              **Costs (euros)**                    **DID**         **Costs (euros)**   **DID**

  ARIMA model                                                                             (2,0,0)\                             (2,1,2)\                             (0,1,2)\                             (1,0,0)\        (0,1,2)\            (0,1,2)\
                                                                                          (2,1,0)                              (0,1,1)                              (0,1,1)                              (2,1,1)         (0,1,1)             (0,1,1)

  AR1                                                                                     0.438 \*\*\*                         −0.441 \*\*\*                        \-                                   0.560 \*\*\*    \-                  \-

  AR2                                                                                     0.098 \*                             −0.292 \*                            \-                                   \-              \-                  \-

  MA1                                                                                     \-                                   −0.151 \*                            0.270 \*\*\*                         \-              −0.052597 \*        −0.040777 \*

  MA2                                                                                     \-                                   −0.841 \*                            0.580 \*\*\*                         \-              −0.547567 \*\*\*    −0.638842 \*\*\*

  SAR1                                                                                    −0.547 \*\*\*                        \-                                   \-                                   −0.194 \*\*     \-                  \-

  SAR2                                                                                    −0.405 \*\*\*                        \-                                   \-                                   −0.374 \*\*\*   \-                  \-

  SMA1                                                                                    \-                                   0.845 \*\*\*                         0.811 \*\*\*                         0.376 \*        −0.521205 \*\*\*    −0.577372 \*\*\*

  V1                                                                                      −0.047 \*                            −0.041 \*                            −0.045 \*                            −0.040 \*       \-                  \-

  Q test (*p*-value, delay 18)                                                            15.412\                              9.606\                               17.420\                              15.011\         16.517\             17.906\
                                                                                          (0.3951)                             (0.7260)                             (0.3214)                             (0.377)         (0.223)             (0.1611)

  AIC                                                                                     −7.222                               −6.511                               −7.182                               −7.147          −18.42              −12.45

  Residual sum of squares                                                                 0.078                                0.088                                0.091                                0.087           0.0615              0.0655

  Standard error of the regression                                                        0.017                                0.026                                0.016                                0.018           0.0807              0.0822

  Effect on the series\                                                                   −9.26%                               −0.277 DID (−6.69%)                  −10.65%                              −0.193 DID\     −14.29%             −0.174 DID\
  (calculations of savings in [Table A6](#antibiotics-09-00423-t0A6){ref-type="table"})                                                                                                                  (−4.19%)                            (−12.30%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend: (\*) significant level equal to or less than 0.05; (\*\*) significance level equal to or less than 0.01; (\*\*\*) level of significance equal to or less than 0.001; ARIMA (integrated autoregressive moving average model); AR1 (first autoregressive term); AR2 (second autoregressive term; MA1 (first moving average term), MA2 (second moving average term); SAR1 (first seasonal autoregressive term); SMA1 (first seasonal moving average term); V1 (dummy variable that takes the value 1 in June 2013 and −1 in July 2013); AIC (Akaike information criterion); DID (daily defined doses per thousand people). Source: Own elaboration from data provided by the Pharmacy Directorate of the Basque Government.

antibiotics-09-00423-t0A6_Table A6

###### 

Saving of the approval of the PRAN by active substance (predictions with the ARIMA models in [Table A5](#antibiotics-09-00423-t0A5){ref-type="table"}).

  ---------------------- -------------------------------- -------------------------------- ------------------------------- ---------------- ---------------- -------------------------------
  **Series**\            **Euros**\                       **DID**\                                                                                           
  **Active Substance**   **Amoxicillin**                  **Amoxicillin**                                                                                    

  **Date**               **Real Value**                   **Prediction**                   **Confidence Interval (80%)**   **Real Value**   **Prediction**   **Confidence Interval (80%)**

  **Jul. 2015**          236,664                          257,412                          240,284--274,540                0.261            0.271            0.264--0.278

  **Aug. 2015**          165,798                          186,423                          169,294--203,552                0.200            0.247            0.240--0.255

  **Sep. 2015**          235,282                          255,462                          238,332--272,592                0.290            0.300            0.293--0.307

  **Oct. 2015**          304,086                          326,475                          308,695--344,255                0.330            0.341            0.334--0.348

  **Nov. 2015**          300,430                          319,920                          302,140--337,700                0.326            0.343            0.336--0.350

  **Dec. 2015**          298,582                          318,720                          301,588--335,852                0.384            0.393            0.386--0.400

  **Jan. 2016**          318,228                          338,012                          320,878--355,146                0.378            0.487            0.480--0.494

  **Feb. 2016**          260,585                          342,410                          324,672--360,148                0.390            0.399            0.392--0.406

  **Mar. 2016**          288,645                          311,984                          294,246--329,722                0.377            0.399            0.392--0.406

  **Apr. 2016**          251,430                          281,903                          264,165--299,641                0.319            0.328            0.321--0.335

  **May 2016**           266,836                          291,412                          273,674--309,150                0.321            0.334            0.324--0.344

  **Jun. 2016**          244,219                          264,347                          246,609--282,085                0.283            0.294            0.284--0.304

  **Total**              **3,170,785**                    **3.494.480**                                                    **3.859**        **4.136**        

  **Difference**         **−323,695**                     **−0.277**                                                                                         

  **Variation**          **−9.26%**                       **−6.69%**                                                                                         

  **Series**\            **Euros**\                       **DID**\                                                                                           
  **Active Substance**   **Amoxicillin and Inhibitors**   **Amoxicillin and Inhibitors**                                                                     

  **Date**               **Real Value**                   **Prediction**                   **Confidence Interval (80%)**   **Real Value**   **Prediction**   **Confidence Interval (80%)**

  **Jul. 2015**          135,686                          143,620                          137,669--149,571                0.336            0.349            0.341--0.357

  **Aug. 2015**          120,658                          134,021                          122,677--145,366                0.302            0.316            0.308--0.324

  **Sep. 2015**          146,708                          160,125                          148,329--171,921                0.339            0.360            0.352--0.368

  **Oct. 2015**          159,832                          174,841                          161,689--187,993                0.384            0.396            0.389--0.403

  **Nov. 2015**          152,695                          170,423                          156,503--184,343                0.381            0.394            0.387--0.401

  **Dec. 2015**          172,782                          191,200                          176,314--206,086                0.428            0.448            0.441--0.455

  **Jan. 2016**          169,610                          187,921                          172,230--203,612                0.455            0.468            0.458--0.478

  **Feb. 2016**          165,837                          184,701                          168,181--201,221                0.403            0.420            0.410--0.430

  **Mar. 2016**          156,092                          177,730                          160,440--195,020                0.401            0.420            0.410--0.430

  **Apr. 2016**          135,329                          158,001                          139,953--176,049                0.338            0.354            0.344--0.364

  **May 2016**           139,558                          161,741                          142,967--180,515                0.331            0.351            0.341--0.361

  **Jun. 2016**          131,058                          154,379                          134,898--173,860                0.329            0.347            0.337--0.357

  **Total**              **1,785,846**                    **1.998.703**                                                    **4.427**        **4,621**        

  **Difference**         **−212,858**                     **−0.193**                                                                                         

  **Variation**          **−10.65%**                      **−4.19%**                                                                                         

  **Series**\            **Euros**\                       **DID**\                                                                                           
  **Active Substance**   **Azithromycin**                 **Azithromycin**                                                                                   

  **Date**               **Real Value**                   **Prediction**                   **Confidence Interval (80%)**   **Real Value**   **Prediction**   **Confidence Interval (80%)**

  **Jul. 2015**          76,836                           86,747                           77,667--95,826                  0.081            0.089            0.082--0.097

  **Aug. 2015**          63,910                           76,970                           64,463--89,477                  0.066            0.078            0.067.20 0.090

  **Sep. 2015**          81,021                           95,662                           82,639--108,685                 0.087            0.101            0.089--0.112

  **Oct. 2015**          95,210                           110,230                          96,711--123,750                 0.101            0.115            0.103--0.127

  **Nov. 2015**          95,016                           109,752                          95,754--123,751                 0.090            0.104            0.092--0.117

  **Dec. 2015**          119,522                          135,372                          120,911--149,834                0.123            0.139            0.126--0.152

  **Jan. 2016**          128,086                          154,055                          139,144--168,965                0.144            0.159            0.145--0.172

  **Feb. 2016**          118,522                          135,161                          119,815--150,507                0.123            0.139            0.126--0.153

  **Mar. 2016**          112,412                          130,740                          114,971--146,510                0.119            0.135            0.121--0.150

  **Apr. 2016**          96,023                           112,525                          96,344--128,707                 0.102            0.117            0.103--0.132

  **May 2016**           94,177                           112,275                          95,691--128,859                 0.101            0.117            0.102--0.132

  **Jun. 2016**          94,204                           111,289                          94,313--128,265                 0.098            0.114            0.099--0.129

  **Total**              **1,174,938**                    **1,370,780**                                                    **1.24055**      **1.414558**     

  **Difference**         **−195,841**                     **−0.17401**                                                                                       

  **Variation**          **−14.29%**                      **−12.30%**                                                                                        
  ---------------------- -------------------------------- -------------------------------- ------------------------------- ---------------- ---------------- -------------------------------

Legend: DID (daily defined doses per thousand people). Source: Own elaboration based on data provided by the Basque Government Pharmacy Department.

![Time series of antibiotic dispensing (€, packages and DID). Black line: monthly prescription values; dashed line: forecasts (80% confidence interval) obtained in counterfactual analysis. Source: Own elaboration based on data provided by the Basque Government Pharmacy Department.](antibiotics-09-00423-g0A1){#antibiotics-09-00423-f0A1}

antibiotics-09-00423-t001_Table 1

###### 

Royal Decree-Law (RDL) no. 16/2012, counterfactual analysis of the series of costs (€), packages, and DID. Real values from January 2009 to May 2013 and predictions from June 2013 to June 2014.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Serie                                                                        Total Costs (euros)                                                                             Total Packages                                                                                   Total DID
  ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------
  ARIMA model                                                                  (0,0,1) (0,1,1)12                                                                               (0,0,1) (0,1,1)12                                                                                (0,0,1) (0,1,1)12

  MA1                                                                          0.519478 \*                                                                                     0.403930 \*                                                                                      0.352600 \*

  SMA1                                                                         0.080095 \*                                                                                     −0.419430 \*\*                                                                                   −0.446311 \*\*

  Q test (*p*-value, delay 18)                                                 10.9600 (0.2785)                                                                                8.9238 (0.4443)                                                                                  8.3222 (0.5020)

  AIC                                                                          −10.681                                                                                         −11.744                                                                                          −11.545

  Residual sum of squares                                                      0.0564                                                                                          0.0796                                                                                           0.0758

  Standard error of the regression                                             0.0395                                                                                          0.0447                                                                                           0.0435

  Effect on the series\                                                        Stockpiling effect of 8.31%\                                                                    Stockpiling effect of 7.21%\                                                                     Stockpiling effect of 7.44%\
  (calculations in [Table A1](#antibiotics-09-00423-t0A1){ref-type="table"})   Savings of 2.20% in expenses, including Jun-13 to Jul-13 (last month with significant effect)   Savings of 12.19% in packages, including Jun-13 to Jun-14 (last month with significant effect)   Savings of 2.07% in DID, including Jun-13 to Jul-13 (last month with significant effect)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend: (\*) significant level equal to or less than 0.05; (\*\*) significance level equal to or less than 0.01; ARIMA (integrated autoregressive moving average model); MA1 (first moving average term); SMA1 (first seasonal moving average term); AIC (Akaike information criteria); DID (daily defined doses per thousand people). Source: Own elaboration based on data provided by the Basque Government Pharmacy Department.

antibiotics-09-00423-t002_Table 2

###### 

National Program Against Bacterial Resistance (PRAN) approval, intervention analysis of the series of costs, packaging, and DID. Real values from January 2009 to June 2015 and predictions from July 2015 to June 2016 with dummy variables V1 and V2.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Serie                                                                        Total Costs (euros)           Total Packages                Total DID
  ---------------------------------------------------------------------------- ----------------------------- ----------------------------- --------------------------------------
  ARIMA model                                                                  (0,1,2) (0,1,1)12             (2,0,0) (2,1,0)12             (1,1,2) (0,1,1)12

  AR1                                                                          \-                            0.340 \*\*\*                  −0.423 \*\*\*

  AR2                                                                          \-                            0.061 \*                      \-

  MA1                                                                          0.490 \*\*\*                  \-                            −0.188 \*

  MA2                                                                          0.381 \*\*\*                  \-                            −0.812 \*

  SAR1                                                                         \-                            −0.446 \*\*                   \-

  SAR2                                                                         \-                            −0.463 \*\*\*                 \-

  SMA1                                                                         0.754 \*\*\*                  \-                            0.772 \*

  V1                                                                           −0.019 \*                     \-                            −0.015 \*

  V2                                                                           \-                            −0.093 \*\*                   \-

  Q test (*p*-value, delay 18)                                                 18.206 (0.252)                18.934 (0.167)                14.701 (0.399)

  AIC                                                                          −7.138                        −7.309                        −7.374

  Residual sum of squares                                                      0.073                         0.076                         0.076

  Standard error of the regression                                             0.020                         0.017                         0.015

  Effect on the series\                                                        Savings of 7.96%\             Savings of 8.87%\             Savings of 0.779 DID\
  (calculations in [Table A2](#antibiotics-09-00423-t0A2){ref-type="table"})   from Jul. 2015 to Jun. 2016   from Jul. 2015 to Jun. 2016   (−4.51% from Jul. 2015 to Jun. 2016)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Legend:** (\*) significant level equal to or less than 0.05; (\*\*) significance level equal to or less than 0.01; (\*\*\*) level of significance equal to or less than 0.001; ARIMA (integrated autoregressive moving average model); AR1 (first autoregressive term); AR2 (second autoregressive term; MA1 (first moving average term); MA2 (second moving average term); SAR1 (first seasonal autoregressive term); SAR2 (second seasonal autoregressive term); SMA1 (first seasonal moving average term); V1 (dummy variable that takes the value 1 in June 2013 and −1 in July 2013); V2 (dummy variable that takes the value 1 in June 2013 and −1 from July 2013 to June 2014); AIC ( information criterion of Akaike); DID (daily defined doses per thousand people). Source: Own elaboration from data provided by the Basque Government Pharmacy Department.
